Key Republican and Democratic lawmakers said Wednesday (Dec. 7) that the Biologics Price Competition and Innovation Act is unlikely to be on the chopping block when Republicans pursue an Affordable Care Act repeal next year. The Republican also cited a lag in FDA issuance of key guidances as a failure of the BPCIA and said Congress may attach language in upcoming user fee authorizations to speed the process along. Sen. Bill Cassidy (R-LA) speaking at an Atlantic policy briefing...